Protara Therapeutics (TARA) Competitors $3.14 -0.06 (-1.88%) Closing price 04:00 PM EasternExtended Trading$3.14 0.00 (0.00%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARA vs. TECX, KOD, ETON, ARCT, RGNX, ITOS, ESPR, CGEM, ERAS, and CYRXShould you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include Tectonic Therapeutic (TECX), Kodiak Sciences (KOD), Eton Pharmaceuticals (ETON), Arcturus Therapeutics (ARCT), REGENXBIO (RGNX), iTeos Therapeutics (ITOS), Esperion Therapeutics (ESPR), Cullinan Therapeutics (CGEM), Erasca (ERAS), and CryoPort (CYRX). These companies are all part of the "pharmaceutical products" industry. Protara Therapeutics vs. Its Competitors Tectonic Therapeutic Kodiak Sciences Eton Pharmaceuticals Arcturus Therapeutics REGENXBIO iTeos Therapeutics Esperion Therapeutics Cullinan Therapeutics Erasca CryoPort Protara Therapeutics (NASDAQ:TARA) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership. Which has more volatility and risk, TARA or TECX? Protara Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 3.42, suggesting that its share price is 242% more volatile than the S&P 500. Which has better earnings and valuation, TARA or TECX? Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtara TherapeuticsN/AN/A-$44.60M-$1.62-1.94Tectonic TherapeuticN/AN/A-$57.98M-$4.04-4.39 Does the media favor TARA or TECX? In the previous week, Tectonic Therapeutic had 3 more articles in the media than Protara Therapeutics. MarketBeat recorded 4 mentions for Tectonic Therapeutic and 1 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.89 beat Tectonic Therapeutic's score of 1.27 indicating that Protara Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Protara Therapeutics Very Positive Tectonic Therapeutic Positive Is TARA or TECX more profitable? Tectonic Therapeutic's return on equity of -30.13% beat Protara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protara TherapeuticsN/A -36.87% -33.85% Tectonic Therapeutic N/A -30.13%-28.33% Do insiders & institutionals hold more shares of TARA or TECX? 38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 8.4% of Protara Therapeutics shares are held by company insiders. Comparatively, 38.0% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer TARA or TECX? Protara Therapeutics currently has a consensus target price of $19.60, suggesting a potential upside of 524.20%. Tectonic Therapeutic has a consensus target price of $80.29, suggesting a potential upside of 353.08%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Protara Therapeutics is more favorable than Tectonic Therapeutic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Tectonic Therapeutic 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 SummaryTectonic Therapeutic beats Protara Therapeutics on 7 of the 13 factors compared between the two stocks. Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARA vs. The Competition Export to ExcelMetricProtara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$123.46M$2.59B$5.86B$10.15BDividend YieldN/A56.51%5.68%4.59%P/E Ratio-1.9423.5374.5225.93Price / SalesN/A697.48539.62123.65Price / CashN/A171.1637.5660.44Price / Book0.665.3712.166.29Net Income-$44.60M$32.95M$3.28B$270.77M7 Day Performance-0.32%1.31%0.98%3.36%1 Month Performance2.28%8.31%7.20%6.41%1 Year Performance81.50%0.29%63.06%28.26% Protara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARAProtara Therapeutics1.5459 of 5 stars$3.14-1.9%$19.60+524.2%+88.2%$123.46MN/A-1.9430TECXTectonic Therapeutic3.207 of 5 stars$25.54-0.1%$80.33+214.5%+3.0%$477.91MN/A-6.32120Positive NewsKODKodiak Sciences3.8534 of 5 stars$9.04+0.8%$11.75+30.0%+301.6%$477.51MN/A-2.3890Positive NewsETONEton Pharmaceuticals1.9929 of 5 stars$17.31+0.2%$29.67+71.4%+266.8%$464.21M$39.01M-108.1920Positive NewsARCTArcturus Therapeutics3.1328 of 5 stars$17.01-1.7%$50.57+197.3%-14.0%$461.90M$152.31M-7.63180Positive NewsGap DownRGNXREGENXBIO4.6648 of 5 stars$8.93-0.9%$28.38+217.7%-25.3%$451.09M$83.33M-2.60370ITOSiTeos Therapeutics3.431 of 5 stars$10.15flat$15.50+52.7%N/A$448.68M$35M-2.1790ESPREsperion Therapeutics4.1061 of 5 stars$2.22+0.5%$7.00+215.3%+60.3%$447.60M$332.31M-4.53200Positive NewsCGEMCullinan Therapeutics2.2423 of 5 stars$7.54-0.9%$26.80+255.4%-63.2%$445.42MN/A-2.3330News CoveragePositive NewsAnalyst ForecastERASErasca2.5561 of 5 stars$1.57flat$4.29+173.0%-47.6%$445.36MN/A-3.49120CYRXCryoPort3.7768 of 5 stars$8.86+2.0%$12.00+35.4%+21.6%$443.59M$228.38M6.661,186Positive NewsInsider Trade Related Companies and Tools Related Companies TECX Alternatives KOD Alternatives ETON Alternatives ARCT Alternatives RGNX Alternatives ITOS Alternatives ESPR Alternatives CGEM Alternatives ERAS Alternatives CYRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARA) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TARA Stock Alerts